GLP-1 and Smoking Cessation: Can Semaglutide Help You Quit Smoking?

The surprising link between GLP-1 and nicotine

GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are best known for weight loss and blood sugar control. But researchers have uncovered something unexpected: these medications may also help people quit smoking.

The connection makes biological sense. GLP-1 receptors are found in brain regions involved in reward and addiction, including the ventral tegmental area and nucleus accumbens — the same dopamine circuits that nicotine hijacks. By modulating these reward pathways, GLP-1 medications may reduce the pleasurable effects of nicotine and dampen cravings.

This is not just theory. A growing body of preclinical and early clinical research supports the potential of GLP-1 therapies for smoking cessation, with a key 2026 clinical trial providing the first human data.

The 2026 semaglutide smoking cessation trial

The most important study to date is a phase 2a randomized clinical trial published in JAMA Network Open in 2026. Researchers at an academic medical center enrolled 45 adults who smoked at least 5 cigarettes per day and were not trying to quit. Participants received either semaglutide or placebo for 9 weeks.

Key findings

• Nicotine craving reduction: Semaglutide significantly reduced cigarette craving compared to placebo (P = 0.01), with the effect growing stronger over the treatment period
• Weight management: Semaglutide produced significant weight loss while placebo participants gained weight — directly addressing the post-quit weight gain that drives relapse
• Reduced smoking in lab: Supplementary analysis showed significantly greater reductions in laboratory smoking behavior (P = 0.02, effect size d = 0.67)
• Withdrawal symptoms: Exploratory analysis suggested potential effects on reducing withdrawal symptoms

The trial's primary endpoints — laboratory measures of smoking resistance and weekly cigarette count — did not reach statistical significance. However, the secondary and exploratory findings were promising enough that researchers called for larger trials to evaluate GLP-1 therapies for cessation.

Why post-quit weight gain matters

Weight gain after quitting smoking is one of the biggest barriers to successful cessation. On average, people gain 5 to 10 pounds in the first 6 months after quitting, and some gain 20+ pounds. This weight gain drives relapse — studies show that 35 to 50 percent of people who quit smoking relapse partly due to weight concerns.

GLP-1 medications address this problem directly. By suppressing appetite and promoting weight loss, they could eliminate the weight-gain barrier that makes quitting so difficult. This dual-action — reducing cravings and preventing weight gain — is something no currently approved smoking cessation medication achieves.

How GLP-1 affects the brain's reward system

The neuroscience behind GLP-1 and addiction is fascinating. GLP-1 receptors are expressed throughout the mesolimbic dopamine system — the brain's reward circuit. When GLP-1 medications activate these receptors, they:

• Reduce dopamine release in response to addictive substances, making nicotine less rewarding
• Decrease cue-induced cravings by attenuating the brain's response to smoking triggers
• Reduce withdrawal hyperphagia — the increased eating that occurs when nicotine's appetite-suppressing effect disappears
• Modulate stress responses that can trigger relapse

A 2026 review in Biological Psychiatry concluded that GLP-1 receptor agonists "warrant consideration for smoking cessation" based on preclinical evidence showing they modulate nicotine reward, reduce self-administration, and prevent withdrawal-related hyperphagia.

Preclinical evidence: what animal studies show

Before human trials, animal research provided strong signals. Key findings include:

• Rodents given semaglutide showed reduced nicotine self-administration
• GLP-1 receptor agonists decreased nicotine-seeking behavior even under stress conditions
• Animals treated with GLP-1 medications gained less weight after nicotine cessation
• The effect was reversed by GLP-1 receptor antagonists, confirming the mechanism

GLP-1 vs. current smoking cessation medications

Current FDA-approved smoking cessation medications have modest success rates. Varenicline (Chantix) and bupropion (Zyban) help about 20 to 25 percent of smokers quit at 6 months. Nicotine replacement therapy (patches, gum) has similar rates. All existing medications have one major limitation: they do not address post-quit weight gain.

Who might benefit from GLP-1 for smoking cessation?

GLP-1 medications are not yet FDA-approved for smoking cessation, but they may be appropriate for people who:

• Have a BMI of 27 or higher and also smoke cigarettes
• Have tried to quit smoking multiple times and relapsed due to weight gain
• Have weight-related health conditions (hypertension, diabetes, sleep apnea) alongside smoking
• Are concerned about post-quit weight gain as a barrier to cessation

If you smoke and have obesity or overweight, GLP-1 treatment could address both conditions simultaneously. A telehealth provider can evaluate whether you qualify for GLP-1 medication based on your BMI and health history.

What to expect if you combine GLP-1 with a quit attempt

If you and your healthcare provider decide to use GLP-1 medication while attempting to quit smoking, here is what the process might look like:

• Weeks 1 to 4: Start GLP-1 at a low titration dose. Begin behavioral smoking cessation support.
• Weeks 4 to 8: Increase GLP-1 dose. Set a quit date. Monitor craving reduction and appetite changes.
• Weeks 8 to 16: At target GLP-1 dose, cravings should be reduced. Weight should be stable or decreasing rather than increasing.
• Months 4 to 6: Sustained cessation with ongoing weight management. Regular check-ins with your provider.

The future of GLP-1 for addiction treatment

The smoking cessation research is part of a broader trend. GLP-1 medications are being investigated for alcohol use disorder, opioid addiction, gambling disorder, and other addictive behaviors. A 2025 study published in JAMA Psychiatry showed semaglutide reduced alcohol consumption in adults with alcohol use disorder. A 2026 study in Criminology found that GLP-1 use was associated with 62 percent reduced relationship between impulsivity and violent crime.

Researchers are now planning larger phase 3 trials specifically for smoking cessation. If these confirm the early findings, GLP-1 medications could become the first smoking cessation treatment that simultaneously addresses weight gain — potentially transforming quit rates.

Frequently asked questions

Can GLP-1 medications help you quit smoking?

Early clinical research suggests GLP-1 medications may reduce nicotine cravings and cigarette consumption. A 2026 phase 2a trial showed semaglutide significantly reduced cigarette craving and body weight, though it did not significantly increase laboratory smoking resistance. Larger trials are needed to confirm cessation effects.

Does semaglutide prevent weight gain after quitting smoking?

Yes. In the 2026 phase 2a trial, participants taking semaglutide maintained or lost weight during the study, while those on placebo gained weight. This is significant because post-quit weight gain is a major barrier to successful smoking cessation.

How does GLP-1 affect nicotine cravings?

GLP-1 receptor agonists modulate the brain's dopamine reward system, which is the same pathway that nicotine activates. By reducing the rewarding effects of nicotine, GLP-1 medications may decrease the urge to smoke and reduce withdrawal-related hyperphagia.

Should I take GLP-1 medication to quit smoking?

GLP-1 medications are not yet FDA-approved for smoking cessation. However, if you are overweight or have obesity and also smoke, GLP-1 treatment may provide dual benefits: weight loss and reduced nicotine cravings. Talk to your healthcare provider about whether this approach is appropriate for you.

Conclusion

The emerging research on GLP-1 medications and smoking cessation is promising. By simultaneously reducing nicotine cravings and preventing post-quit weight gain, GLP-1 therapies could address the two biggest barriers to quitting smoking. While larger clinical trials are needed before GLP-1 medications are approved for cessation, people who have obesity and smoke may benefit from GLP-1 treatment right now. If you qualify, a telehealth provider can help you start a GLP-1 program that supports both weight loss and smoking reduction.